The specialized endothelial cells that line the blood vessels in the lung may hold the key to treating the common and often-fatal lung disease emphysema, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The genetic changes that underlie an especially lethal type of prostate cancer, called neuroendocrine prostate cancer, have been revealed in a new study at Weill Cornell Medicine. Learning more about what causes this type of cancer could lead to new approaches for treating it.
Black patients who have chronic liver failure, also known as end-stage liver disease, are less likely to be placed on a waiting list for a life-saving liver transplant than other racial and ethnic groups, according to a study.
New research from NewYork-Presbyterian and Weill Cornell Medicine identified economic and social conditions impacting individual and group differences in health status, known as social determinants of health.
A two-year, $200,000 grant from the USDA and the Extension Foundation to Cornell researchers aims to help promote vaccine confidence and uptake in vulnerable communities in eight New York counties, both upstate and downstate.
Building on a legacy of groundbreaking advances in medicine and science, Weill Cornell Medicine today launched a $1.5 billion campaign that will harness emerging biomedical innovations to bring exemplary care to patients and create enduring change in medicine.
Cornell Tech awarded four student startup companies with pre-seed funding worth up to $100,000 in its eighth annual Startup Awards competition, announced at Cornell Tech’s virtual Open Studio, held May 26.